ARTICLE | Clinical News
ETBX-011: Phase I/II data
May 28, 2012 7:00 AM UTC
An open-label, U.S. Phase I/II trial in 25 patients with refractory advanced CEA-expressing colorectal cancer showed that subcutaneous ETBX-011 given once every 3 weeks for 3 doses led to a 1-year ove...